ID Source | ID |
---|---|
PubMed CID | 158629 |
CHEMBL ID | 3182045 |
MeSH ID | M0065498 |
Synonym |
---|
59536-65-1 |
2,3,3',4,4',5'-hexabromobiphenyl |
firemaster bp-6 |
firemaster bp 6 |
1,2,3-tribromo-4-(3,4,5-tribromophenyl)benzene |
dsstox_gsid_21174 |
NCGC00260144-01 |
dsstox_rid_75991 |
tox21_202596 |
cas-59536-65-1 |
dsstox_cid_1174 |
1,1'-biphenyl, 2,3,3',4,4',5'-hexabromo- |
1dfm7va843 , |
unii-1dfm7va843 |
84303-47-9 |
2,3,3',4,4',5'-hexabromo-1,1'-biphenyl |
pbb 157 |
CHEMBL3182045 |
Q26840774 |
DTXSID20860744 |
Excerpt | Reference | Relevance |
---|---|---|
" No adverse maternal effects were observed nor were there PBB-related effects on survival of the F1 generation or acquisition of developmental landmarks." | ( Developmental neurotoxicity of polybrominated biphenyls. Carlson, CL; Henck, JW; Mattsson, JL; Rech, RH; Rezabek, DH, ) | 0.13 |
Toxicity was induced by dosing two Holstein cows with 25 g of fireMaster BP-6/d for 39 or 50 d.
Excerpt | Relevance | Reference |
---|---|---|
" Microsomal lipids were markedly altered in the polybrominated biphenyl- (PBB-) dosed animals at the earliest time examined (1 wk), and these changes persisted throughout the remainder of the study." | ( Acute response of rat liver microsomal lipids, lipid peroxidation, and membrane anisotropy to a single oral dose of polybrominated biphenyls. Bernert, JT; Groce, DF, 1984) | 0.27 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 26.2196 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.7315 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 21.0136 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 26.8849 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 5.3642 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 5.5685 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 33.8460 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 16.5967 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 30.1653 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 23.5740 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743078 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 27.1216 | 0.0010 | 19.4141 | 70.9645 | AID743094 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 7.1469 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 49.7220 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 26.8849 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 23.9612 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 13 (76.47) | 18.7374 |
1990's | 4 (23.53) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.27) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |